Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial.

Microbiology and Gut Biology Group, University of Dundee, Ninewells Hospital Medical School, Dundee DD1 9SY, UK.
Gut (Impact Factor: 13.32). 03/2005; 54(2):242-9. DOI: 10.1136/gut.2004.044834
Source: PubMed

ABSTRACT Ulcerative colitis (UC) is an acute and chronic inflammatory disease of the large bowel with unknown aetiology. The immune response against normal commensal microorganisms is believed to drive inflammatory processes associated with UC. Therefore, modulation of bacterial communities on the gut mucosa, through the use of probiotics and prebiotics, may be used to modify the disease state.
A synbiotic was developed for use in UC patients combining a probiotic, Bifidobacterium longum, isolated from healthy rectal epithelium, and a prebiotic (Synergy 1), a preferential inulin-oligofructose growth substrate for the probiotic strain. Treatment was employed in a double blinded randomised controlled trial using 18 patients with active UC for a period of one month. Clinical status was scored and rectal biopsies were collected before and after treatment, and transcription levels of epithelium related immune markers were measured.
Sigmoidoscopy scores (scale 0-6) were reduced in the test group (start 4.5 (1.4), end 3.1 (2.5)) compared with placebo (start 2.6 (2.1), end 3.2 (2.2)) (p=0.06). mRNA levels for human beta defensins 2, 3, and 4, which are strongly upregulated in active UC, were significantly reduced in the test group after treatment (p=0.016, 0.038, and 0.008, respectively). Tumour necrosis factor alpha and interleukin 1alpha, which are inflammatory cytokines that drive inflammation and induce defensin expression, were also significantly reduced after treatment (p=0.018 and 0.023, respectively). Biopsies in the test group had reduced inflammation and regeneration of epithelial tissue.
Short term synbiotic treatment of active UC resulted in improvement of the full clinical appearance of chronic inflammation in patients receiving this therapy.

Download full-text


Available from: Elizabeth Furrie, Aug 14, 2014
  • Source
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Barrett's oesophagus (BO) is a complicated condition at gastroesophageal junction in which normal squamous epithelium is changed to columnar and leads to oesophageal adenocarcinoma (OA). In the past decades, prevalence of Barrett's disease and mortality rate of adenocarcinoma has significantly increased through the word. Data represent that molecular pathogenesis of disease has not been clearly identified. However, wide range and successful administration of probiotics in cancer and gastrointestinal diseases lead to create the idea of investigation possible inhibitory role of probiotics to inhibit oesophageal cancer. This study was conducted to evaluate the inhibition effect of probiotics on the expression of biomarkers in in vitro model. Two different Barrett's oesophageal cell lines were selected to co-culture with Bifidobacterium longum and Lactobacillus acidophilus to measure expression of IL18 (interleukin 18), TNFα (tumour necrosis factor-α), p53 (tumour suppressor gene), COX2 (cyclooxygenase 2), and CDX1 (caudal type homeobox 1) genes. In addition, two different aspects of probiotic administration, therapeutic and prophylactic test was also examined. Results showed that microorganisms could inhibit expression of biomarkers, and therapeutic culture condition was more effective than prophylactic test. Obtained results suggest that it is possibility to apply administration of probiotics in BO and OA prevention.
    Journal of Medical Microbiology 02/2015; 64(Pt_4). DOI:10.1099/jmm.0.000039 · 2.27 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Over the past recent years, a great number of studies have been directed toward the evaluation of the human host-gut microbiota interaction, with the goal to progress the understanding of the etiology of several complex diseases. Alterations in the intestinal microbiota associated with inflammatory bowel disease are well supported by literature data and have been widely accepted by the research community. The concomitant implementation of high-throughput sequencing techniques to analyze and characterize the composition of the intestinal microbiota has reinforced the view that inflammatory bowel disease results from altered interactions between gut microbes and the mucosal immune system and has raised the possibility that some form of modulation of the intestinal microbiota may constitute a potential therapeutic basis for the disease. The aim of this review is to describe the changes of gut microbiota in inflammatory bowel disease, focusing the attention on its involvement in the pathogenesis of the disease, and to review and discuss the therapeutic potential to modify the intestinal microbial population with antibiotics, probiotics, prebiotics, synbiotics and fecal microbiota transplantation.
    Pharmacology [?] Therapeutics 01/2015; 149. DOI:10.1016/j.pharmthera.2014.12.006 · 7.75 Impact Factor